Rznomics Reports Major Advances in High-Efficiency Circular RNA Production in Nucleic Acids Research

Rznomics reported that engineering its proprietary self-targeting and splicing circRNA platform improved circularization efficiency by up to approximately seven-fold versus its original design. For a 7.8-kilonucleotide Factor VIII RNA, the optimized method delivered roughly two-times the circularization efficiency of the widely used PIE approach. The peer-reviewed results could broaden the company’s circRNA platform for vaccines, protein therapeutics and CAR-T applications, although no clinical or financial milestones were disclosed.

Analysis

The publication modestly improves Rznomics' partnering narrative, but it does not change the investable thesis for LLY absent evidence that the existing collaboration covers this platform, contains circRNA option rights, or generates milestone economics. For LLY, the relevant sensitivity is immaterial near term: a discovery-stage manufacturing advance cannot affect consensus revenue, margin, or pipeline probability without a named program and development timeline. The more relevant read-through is that large-RNA manufacturability remains a gating issue for the broader RNA field, so reproducible yield, impurity profile, and cost-per-dose—not laboratory circularization efficiency—will determine commercial value.

Competitive implications are most relevant to RNA-platform developers such as MRNA, BNTX and ARCT, whose valuations embed varying degrees of platform optionality. A credible solution for longer constructs could eventually expand the addressable set toward protein replacement and cell-therapy engineering, but it may also lower differentiation for incumbent RNA delivery and manufacturing platforms if the method proves broadly licensable. Over the next 1-3 months, this is principally a Korean small-cap liquidity and licensing-news catalyst rather than a catalyst for US-listed RNA names; over 6-18 months, validation in an IND-enabling program, external replication, and a commercial partnership would be required before assigning material platform value.

The contrarian view is that peer-reviewed process innovation is often overcapitalized relative to its translational value. Circular RNA programs still face delivery, innate-immune activation, expression consistency, and CMC comparability hurdles; improved formation yield can be offset by purification losses or reduced functional expression. The thesis is falsified positively by disclosed third-party adoption and manufacturing-scale data, and negatively by any failure to convert the work into a partnered candidate, milestone payment, or clinical program within the next 12 months.

Key Decisions for Investors

• No incremental LLY position on this item. Maintain LLY exposure based on core metabolic and pipeline drivers; reassess only if Rznomics discloses that the collaboration includes circRNA rights, a funded candidate, or a milestone with quantified economics.
• Place a 6-12 month event-driven watch on Rznomics (KOSDAQ: 476830): consider a small liquidity-adjusted long only after confirmation of an external license, upfront payment, or IND nomination. Require evidence of scaled manufacturing yield, purity, and functional-expression data; publication-driven price strength alone is not sufficient.
• Avoid treating MRNA, BNTX, or ARCT as direct beneficiaries. A long RNA-platform basket would require independent evidence that long-circRNA production improves delivery-adjusted potency or expands a funded development program; otherwise the likely near-term effect is narrative rotation, not earnings revision.
• For any Rznomics event trade, use the post-publication high as a risk marker and cap exposure given KOSDAQ liquidity and binary partnering risk. Take profits into partnership-rumor spikes unless terms include meaningful non-refundable upfront cash or development milestones.